Cargando…
Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.
Recent biochemical and pharmacological findings concerning tamoxifen (TMX) have proven that both the unchanged drug and the main metabolites, N-desmethyltamoxifen (NDT) and 4-hydroxytamoxifen (4OHT) are biologically active. An HPLC method based on on-line post-column UV irradiation with fluorescence...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1987
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001713/ https://www.ncbi.nlm.nih.gov/pubmed/3606944 |
_version_ | 1782135660913623040 |
---|---|
author | Milano, G. Etienne, M. C. Frenay, M. Khater, R. Formento, J. L. Renee, N. Moll, J. L. Francoual, M. Berto, M. Namer, M. |
author_facet | Milano, G. Etienne, M. C. Frenay, M. Khater, R. Formento, J. L. Renee, N. Moll, J. L. Francoual, M. Berto, M. Namer, M. |
author_sort | Milano, G. |
collection | PubMed |
description | Recent biochemical and pharmacological findings concerning tamoxifen (TMX) have proven that both the unchanged drug and the main metabolites, N-desmethyltamoxifen (NDT) and 4-hydroxytamoxifen (4OHT) are biologically active. An HPLC method based on on-line post-column UV irradiation with fluorescence detection is described. Optimized conditions allowed complete and rapid separation of TMX 4OHT, NDT and two other recently reported metabolites, Y and Z. This method was applied to plasma and cytosol drug and metabolite analyses. In plasma, from the moment of initial drug administration until the steady state (after 1 month or more of continuous oral TMX treatment), the values of NDT to TMX ratios were completely reversed: 22 to 215 in mean %, P less than 0.01. The presence of metabolites Y and Z is significant. 4OHT, hardly detectable at the first dose, was measured at the steady state with high interpatient variability. It is hypothesized that metabolite evolution with time may be due to auto-induction of drug metabolism. In cytosols, which were all obtained during continuous TMX treatment, the ratios between TMX and metabolites were comparable to those observed in plasma, but with greater interpatient variability. Metabolite Y was not detectable in cytosols. This variability was not linked to the levels of cytosolic oestradiol receptors before initiation of treatment. |
format | Text |
id | pubmed-2001713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1987 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20017132009-09-10 Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. Milano, G. Etienne, M. C. Frenay, M. Khater, R. Formento, J. L. Renee, N. Moll, J. L. Francoual, M. Berto, M. Namer, M. Br J Cancer Research Article Recent biochemical and pharmacological findings concerning tamoxifen (TMX) have proven that both the unchanged drug and the main metabolites, N-desmethyltamoxifen (NDT) and 4-hydroxytamoxifen (4OHT) are biologically active. An HPLC method based on on-line post-column UV irradiation with fluorescence detection is described. Optimized conditions allowed complete and rapid separation of TMX 4OHT, NDT and two other recently reported metabolites, Y and Z. This method was applied to plasma and cytosol drug and metabolite analyses. In plasma, from the moment of initial drug administration until the steady state (after 1 month or more of continuous oral TMX treatment), the values of NDT to TMX ratios were completely reversed: 22 to 215 in mean %, P less than 0.01. The presence of metabolites Y and Z is significant. 4OHT, hardly detectable at the first dose, was measured at the steady state with high interpatient variability. It is hypothesized that metabolite evolution with time may be due to auto-induction of drug metabolism. In cytosols, which were all obtained during continuous TMX treatment, the ratios between TMX and metabolites were comparable to those observed in plasma, but with greater interpatient variability. Metabolite Y was not detectable in cytosols. This variability was not linked to the levels of cytosolic oestradiol receptors before initiation of treatment. Nature Publishing Group 1987-05 /pmc/articles/PMC2001713/ /pubmed/3606944 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Milano, G. Etienne, M. C. Frenay, M. Khater, R. Formento, J. L. Renee, N. Moll, J. L. Francoual, M. Berto, M. Namer, M. Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. |
title | Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. |
title_full | Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. |
title_fullStr | Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. |
title_full_unstemmed | Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. |
title_short | Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. |
title_sort | optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001713/ https://www.ncbi.nlm.nih.gov/pubmed/3606944 |
work_keys_str_mv | AT milanog optimisedanalysisoftamoxifenanditsmainmetabolitesintheplasmaandcytosolofmammarytumours AT etiennemc optimisedanalysisoftamoxifenanditsmainmetabolitesintheplasmaandcytosolofmammarytumours AT frenaym optimisedanalysisoftamoxifenanditsmainmetabolitesintheplasmaandcytosolofmammarytumours AT khaterr optimisedanalysisoftamoxifenanditsmainmetabolitesintheplasmaandcytosolofmammarytumours AT formentojl optimisedanalysisoftamoxifenanditsmainmetabolitesintheplasmaandcytosolofmammarytumours AT reneen optimisedanalysisoftamoxifenanditsmainmetabolitesintheplasmaandcytosolofmammarytumours AT molljl optimisedanalysisoftamoxifenanditsmainmetabolitesintheplasmaandcytosolofmammarytumours AT francoualm optimisedanalysisoftamoxifenanditsmainmetabolitesintheplasmaandcytosolofmammarytumours AT bertom optimisedanalysisoftamoxifenanditsmainmetabolitesintheplasmaandcytosolofmammarytumours AT namerm optimisedanalysisoftamoxifenanditsmainmetabolitesintheplasmaandcytosolofmammarytumours |